Argos Therapeutics Logo

Email this page: News Release

Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of Rocapuldencel-T in Metastatic Renal Cell Carcinoma for Futility Following Its Planned Interim Data Review

For security reasons, registration is required before you can use this feature.
* Indicates required field